• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real-world setting.

作者信息

Papp K A, Gooderham M J, Albrecht L E, Raymond M-A, Lynde C W

机构信息

Probity Medical Research, Waterloo, ON, Canada.

K. Papp Clinical Research, Waterloo, ON, Canada.

出版信息

Br J Dermatol. 2022 Apr;186(4):726-728. doi: 10.1111/bjd.20885. Epub 2022 Jan 20.

DOI:10.1111/bjd.20885
PMID:34748637
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9374060/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9ce/9374060/8b9c2b0a113f/BJD-186-726-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9ce/9374060/8b9c2b0a113f/BJD-186-726-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9ce/9374060/8b9c2b0a113f/BJD-186-726-g001.jpg

相似文献

1
Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real-world setting.在现实环境中，对于对阿达木单抗反应欠佳的银屑病患者，在阿达木单抗基础上加用甲氨蝶呤的治疗满意度、安全性及有效性。
Br J Dermatol. 2022 Apr;186(4):726-728. doi: 10.1111/bjd.20885. Epub 2022 Jan 20.
2
Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.阿达木单抗联合甲氨蝶呤治疗银屑病的优化方案（OPTIMAP）：一项实用、单盲、研究者发起的随机对照试验的研究方案
Trials. 2017 Feb 2;18(1):52. doi: 10.1186/s13063-017-1777-y.
3
Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study.一项随机、双盲、III期研究：阿达木单抗在重度慢性斑块状银屑病儿科患者中的长期持续疗效和安全性
Br J Dermatol. 2019 Dec;181(6):1177-1189. doi: 10.1111/bjd.18029. Epub 2019 Jul 25.
4
Impact of methotrexate and adalimumab on immune function of patients with psoriasis.甲氨蝶呤和阿达木单抗对银屑病患者免疫功能的影响。
Dermatol Ther. 2022 Mar;35(3):e15284. doi: 10.1111/dth.15284. Epub 2022 Jan 8.
5
Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.接受生物疗法治疗的银屑病患者发生主要心血管事件的风险：一项前瞻性队列研究。
J Eur Acad Dermatol Venereol. 2020 Apr;34(4):769-778. doi: 10.1111/jdv.16018. Epub 2019 Nov 19.
6
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).阿达木单抗对比甲氨蝶呤对比安慰剂治疗银屑病患者的随机对照比较研究（CHAMPION）的疗效和安全性结果
Br J Dermatol. 2008 Mar;158(3):558-66. doi: 10.1111/j.1365-2133.2007.08315.x. Epub 2007 Nov 28.
7
Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.儿童顽固性银屑病的系统治疗：病例系列及文献综述
J Drugs Dermatol. 2015 Aug;14(8):881-6.
8
Adalimumab-Induced Pityriasis Lichenoides Chronica That Responded Well to Methotrexate in a Patient With Psoriasis.阿达木单抗诱发的慢性苔藓样糠疹，一名银屑病患者对甲氨蝶呤反应良好
Actas Dermosifiliogr. 2016 Mar;107(2):167-9. doi: 10.1016/j.ad.2015.07.011. Epub 2015 Oct 29.
9
Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.阿达木单抗每两周 1 次与甲氨蝶呤每周 1 次治疗儿童和青少年重度慢性斑块状银屑病的疗效和安全性：一项随机、双盲、3 期临床试验。
Lancet. 2017 Jul 1;390(10089):40-49. doi: 10.1016/S0140-6736(17)31189-3. Epub 2017 May 4.
10
Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.接受过或未对先前全身治疗产生反应的银屑病患者中阿达木单抗的疗效：三项双盲、安慰剂对照临床试验结果的汇总事后分析
Am J Clin Dermatol. 2016 Feb;17(1):79-86. doi: 10.1007/s40257-015-0161-5.

引用本文的文献

1
Identification of neutrophil extracellular traps genes as potential biomarkers in psoriasis based on bioinformatics analysis.基于生物信息学分析鉴定中性粒细胞胞外诱捕网基因作为银屑病的潜在生物标志物。
Sci Rep. 2024 Oct 11;14(1):23848. doi: 10.1038/s41598-024-75069-x.
2
Research hotspots and trends in biological agents for psoriasis: Visualization and bibliometric analysis.银屑病生物制剂的研究热点与趋势：可视化与文献计量分析
Heliyon. 2024 May 14;10(11):e31054. doi: 10.1016/j.heliyon.2024.e31054. eCollection 2024 Jun 15.

本文引用的文献

1
Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan.在日本初治的早期类风湿关节炎患者中启动阿达木单抗加≥12毫克/周甲氨蝶呤并采用可调剂量方案的有效性和安全性：HAWK研究上市后监测
Mod Rheumatol. 2019 Jul;29(4):572-580. doi: 10.1080/14397595.2018.1500979. Epub 2018 Sep 11.
2
Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network.银屑病生物制剂治疗满意度高：来自 Bio-CAPTURE 网络的结果。
Br J Dermatol. 2014 May;170(5):1158-65. doi: 10.1111/bjd.12862.
3
Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study.
严重斑块型银屑病患者生物治疗的临床改善和满意度：一项欧洲横断面观察性研究结果。
J Dermatolog Treat. 2013 Jun;24(3):193-8. doi: 10.3109/09546634.2012.697112. Epub 2012 Sep 21.
4
Canadian guidelines for the management of plaque psoriasis: overview.加拿大斑块型银屑病管理指南：概述。
J Cutan Med Surg. 2011 Jul-Aug;15(4):210-9. doi: 10.2310/7750.2011.10066.
5
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).优特克单抗（一种人白细胞介素-12/23单克隆抗体）治疗银屑病患者的疗效和安全性：一项随机、双盲、安慰剂对照试验（PHOENIX 1）的76周结果
Lancet. 2008 May 17;371(9625):1665-74. doi: 10.1016/S0140-6736(08)60725-4.
6
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.阿达木单抗治疗中重度银屑病：一项随机对照III期试验。
J Am Acad Dermatol. 2008 Jan;58(1):106-15. doi: 10.1016/j.jaad.2007.09.010. Epub 2007 Oct 23.